<scp>RGTA</scp> in corneal wound healing after transepithelial laser ablation in a rabbit model: a randomized, blinded, placebo‐controlled study

Xeroudaki, Maria; Peebo, Beatrice Bourghardt; Germundsson, Johan; Lagali, Neil

doi:10.1111/aos.13116

Cited by 8 publications

(11 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In rabbits it facilitated cornea healing after alkali injuring [11]. Other studies showed no change in healing time in humans [2], rabbits [30], and dogs [28], which is in accordance with our results. Corneal epithelialisation was neither promoted nor impaired.…”

Section: Rgtasupporting

confidence: 93%

“…RGTAs have an antifibrotic effect, bind to extracellular matrix proteins thereby protecting them from proteolysis. They are also known to stimulate wound healing by enhancing growth factors and cytokines to act at the injured site [ [30] and have been used with varying success in other species such as humans, dogs, and rabbits. Cacicol ® is used in human ophthalmology as an adjunctive agent to successfully treat non-healing epithelial defects which occurred secondary to fungal corneal ulcers [20] and neutrotrophic ulcers [1] [18].…”

Section: Rgtamentioning

confidence: 99%

“…In the last decade, the usage of medical substances which enhance speed and quality of tissue healing has been investigated. The improvement in healing times with the use of topically applied regenerating agents (RGTAs) has been evaluated in several species such as humans, dogs, and rabbits and showed conflicting results [ [30]. By replacing and mimicking degraded heparin-sulfate, which is bound to extracellular matrix proteins thus protecting them from proteolysis, RGTAs stimulate the regeneration process [18] [28].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Equine non-healing corneal ulcers: a retrospective evaluation of 57 cases (2001–2017)

Prucha

Tichy

Nell

2020

Tierarztl Prax Ausg G Grosstiere Nutztiere

View full text Add to dashboard Cite

Background and objectives Non-healing corneal ulcers (NHCU) are a common problem in equine practice and several treatment options are available with different success and healing times. The aim of this retrospective study was to evaluate and to compare treatment protocols, clinical courses, corneal healing time and outcomes of NHCU. Methods From December 2001 to December 2017, a total of 57 horses with NHCU were presented at the Vetmeduni Vienna. Recorded data included affected eye, signalment, clinical symptoms, season of diagnosis, treatment protocols, complications and corneal healing rate. Results Sixty-three eyes were diagnosed with a NHCU. Follow-up information was available for 48/63 eyes. For those treated medically mean corneal healing time was 15.7 days (± SD 12.0). Medical treatment included topical antibiotics, antimycotics, cycloplegics, and systemic anti-inflammatory drugs. Twelve eyes received treatment with a poly-carboxymethylglucose-sulfate regenerating agent (Cacicol®; Thea Pharma GmbH, Wien, Austria). Other common additional treatments included debridement with an iodine drenched cotton tip (48 eyes; 76.2 %) and diamond burr debridement (30 eyes; 47.6 %). A bandage contact lens (BCL) was used for 10 eyes. Each eye received at least one additional treatment, although none of them led to a statistically significant alteration in healing time. Only usage of a BCL significantly increased healing time when compared to not using a BCL (p = 0.035). When all treatments failed, superficial keratectomy with placement of a conjunctival flap was performed. Secondary complications included stromal cellular infiltration, keratomycosis, keratomalacia, and corneal abscess formation. Conclusions Results correlated with those previously described and thus demonstrated the difficulty and complexity of this disease. Further research is needed to determine an optimal treatment protocol for non-healing ulcers in horses. Clinical relevance Since NHCUs are a commonly encountered problem in equine practice a reliable treatment protocol is required. This study reflects the problems with those ulcers and provides several protocols for possible treatments.

show abstract

Section: Rgtasupporting

confidence: 93%

Section: Rgtamentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Equine non-healing corneal ulcers: a retrospective evaluation of 57 cases (2001–2017)

Prucha

Tichy

Nell

2020

Tierarztl Prax Ausg G Grosstiere Nutztiere

View full text Add to dashboard Cite

show abstract

“…The product was administered topically once a week for 1 month and resulted in significant reduction in pain, improvement of keratitis, and healing of the majority of corneal ulcers. Several case reports using RGTA ® in cases of neurotrophic keratopathy and corneal ulcers since then have indicated a positive effect of the treatment [26,[29][30][31]. The effectiveness of RGTA ® in corneal neurotrophic ulcers of various primary etiologies was also examined in a larger study with 11 patients, where RGTA ® treatment resulted in complete corneal healing in eight patients, with the remaining patients presenting the most severe cases [8].…”

Section: Discussionmentioning

confidence: 99%

Case Reports for Topical Treatment of Corneal Ulcers with a New Matrix Therapy Agent or RGTA® in Dogs

Martinez¹,

Chiappini²,

Barritault

2019

Veterinary Sciences

View full text Add to dashboard Cite

Superficial corneal ulcers that fail to heal within a normal time period and are refractory to conventional therapy in dogs are common in veterinary practice. Different etiologies can lead to this result, including spontaneous chronic corneal epithelial defects (SCCEDs) and ulcerative keratitis associated with bullous keratopathy. Thus, there is an urgent need to find new therapeutic approaches such as matrix therapy replacement. To determine the efficacy of a new ophthalmic treatment (Clerapliq ® ) for SCCEDs and ulcerative keratitis associated with bullous keratopathy, a total of 11 dogs referred to the clinic because of nonhealing erosive ulcers after a classic primary treatment were enrolled to get this new treatment. Dogs underwent ophthalmic exams and 7 dogs (10 eyes) were diagnosed with superficial ulceration and 4 dogs (5 eyes) with bullous keratopathy due to endothelial dystrophy/degeneration. They received eye drops of Clerapliq ® every 3 days until recovery. The results showed that the corneas with recurrences of the ulcers were resolved predominantly by using Clerapliq ® every 3 days in 83.3% of the cases during a period of treatment ranging between 6 to 35 days. Therefore, this new approach using matrix therapy regenerating technology in treating superficial ulcers and bullous keratopathy in dogs can be successfully considered as an adjunctive therapy.

show abstract

“…Thus, RGTA is conceivably helpful for restoring equilibrium in cellular microenvironment [ 99 , 101 ]. It is also expected to be useful for corneal wound healing, and several studies have shown promising results [ 99 – 107 ].…”

Section: Growth Factors For Corneal Diseasesmentioning

confidence: 99%

Application of Novel Drugs for Corneal Cell Regeneration

Han

Liu

Mohamed-Noriega

2018

Journal of Ophthalmology

View full text Add to dashboard Cite

Corneal transplantation has been the only treatment method for corneal blindness, which is the major cause of reversible blindness. However, despite the advancement of surgical techniques for corneal transplantation, demand for the surgery can never be met due to a global shortage of donor cornea. The development of bioengineering and pharmaceutical technology provided us with novel drugs and biomaterials that can be used for innovative treatment methods for corneal diseases. In this review, the authors will discuss the efficacy and safety of pharmacologic therapies, such as Rho-kinase (ROCK) inhibitors, blood-derived products, growth factors, and regenerating agent on corneal cell regeneration. The promising results of these agents suggest that these can be viable options for corneal reconstruction and visual rehabilitation.

show abstract

RGTA in corneal wound healing after transepithelial laser ablation in a rabbit model: a randomized, blinded, placebo‐controlled study

Cited by 8 publications

References 19 publications

Equine non-healing corneal ulcers: a retrospective evaluation of 57 cases (2001–2017)

Equine non-healing corneal ulcers: a retrospective evaluation of 57 cases (2001–2017)

Case Reports for Topical Treatment of Corneal Ulcers with a New Matrix Therapy Agent or RGTA® in Dogs

Application of Novel Drugs for Corneal Cell Regeneration

Contact Info

Product

Resources

About